Supplementary Figure S1 from JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC

Authors:

Open Access

Cell viability curve for treatment of JIN-A02 in Ba/F3 cell lines with EGFR mutations containing C797S